BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1704251)

  • 1. The value of anticarcinoembryonic antigen, human milk factor globulin, and antikeratin antibodies in differentiating mesothelioma from lung carcinoma.
    Joglekar VM; Oliver D; Harris M
    Br J Ind Med; 1991 Jan; 48(1):34-7. PubMed ID: 1704251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies.
    Ghosh AK; Gatter KC; Dunnill MS; Mason DY
    J Clin Pathol; 1987 Jan; 40(1):19-25. PubMed ID: 2434531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
    Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
    Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocytological staining reactions of anti-carcinoembryonic antigen, Ca, and anti-human milk fat globule monoclonal antibodies on benign and malignant exfoliated mesothelial cells.
    Ghosh AK; Butler EB
    J Clin Pathol; 1987 Dec; 40(12):1424-7. PubMed ID: 3323250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium.
    Marshall RJ; Herbert A; Braye SG; Jones DB
    J Clin Pathol; 1984 Nov; 37(11):1215-21. PubMed ID: 6094617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.
    Otis CN; Carter D; Cole S; Battifora H
    Am J Surg Pathol; 1987 Jun; 11(6):445-56. PubMed ID: 2438954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
    Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
    Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
    Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
    Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
    Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
    Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
    Dejmek A; Hjerpe A
    Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
    Wirth PR; Legier J; Wright GL
    Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
    Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
    J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung.
    Tron V; Wright JL; Churg A
    Arch Pathol Lab Med; 1987 Mar; 111(3):291-3. PubMed ID: 2435259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
    Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
    Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry in the diagnosis of malignant mesothelioma.
    Pfaltz M; Odermatt B; Christen B; Rüttner JR
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma.
    Spagnolo DV; Whitaker D; Carrello S; Radosevich JA; Rosen ST; Gould VE
    Am J Clin Pathol; 1991 Mar; 95(3):322-9. PubMed ID: 1705090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.